Multi-parametric assessment of the anti-angiogenic effects of liposomal glucocorticoids

E. Kluza, M. Heisen, S. Schmid, D.W.J. Schaft, van der, R.M. Schiffelers, G. Storm, B.M. Haar Romeny, ter, G.J. Strijkers, K. Nicolay

Research output: Contribution to journalArticleAcademicpeer-review

6 Citations (Scopus)
53 Downloads (Pure)

Abstract

Inflammation plays a prominent role in tumor growth. Anti-inflammatory drugs have therefore been proposed as anti-cancer therapeutics. In this study, we determined the anti-angiogenic activity of a single dose of liposomal prednisolone phosphate (PLP-L), by monitoring tumor vascular function and viability over a period of one week. C57BL/6 mice were inoculated subcutaneously with B16F10 melanoma cells. Six animals were PLP-L-treated and six served as control. Tumor tissue and vascular function were probed using MRI before and at three timepoints after treatment. DCE-MRI was used to determine Ktrans, ve, time-to-peak, initial slope and the fraction of non-enhancing pixels, complemented with immunohistochemistry. The apparent diffusion coefficient (ADC), T2 and tumor size were assessed with MRI as well. PLP-L treatment resulted in smaller tumors and caused a significant drop in Ktrans 48 h post-treatment, which was maintained until one week after drug administration. However, this effect was not sufficient to significantly distinguish treated from nontreated animals. The therapy did not affect tumor tissue viability but did prevent the ADC decrease observed in the control group. No evidence for PLP-L-induced tumor vessel normalization was found on histology. Treatment with PLP-L altered tumor vascular function. This effect did not fully explain the tumor growth inhibition, suggesting a broader spectrum of PLP-L activities.
Original languageEnglish
Pages (from-to)143-153
JournalAngiogenesis
Volume14
Issue number2
DOIs
Publication statusPublished - 2011

Fingerprint

Glucocorticoids
Tumors
Neoplasms
Magnetic resonance imaging
Blood Vessels
Animals
Therapeutics
Tissue
Histology
Tissue Survival
Pharmaceutical Preparations
Growth
Inbred C57BL Mouse
Anti-Inflammatory Agents
Melanoma
Pixels
Immunohistochemistry
Inflammation
Monitoring
Control Groups

Cite this

Kluza, E. ; Heisen, M. ; Schmid, S. ; Schaft, van der, D.W.J. ; Schiffelers, R.M. ; Storm, G. ; Haar Romeny, ter, B.M. ; Strijkers, G.J. ; Nicolay, K. / Multi-parametric assessment of the anti-angiogenic effects of liposomal glucocorticoids. In: Angiogenesis. 2011 ; Vol. 14, No. 2. pp. 143-153.
@article{459dfc0c7f36450ca8418826b24e2093,
title = "Multi-parametric assessment of the anti-angiogenic effects of liposomal glucocorticoids",
abstract = "Inflammation plays a prominent role in tumor growth. Anti-inflammatory drugs have therefore been proposed as anti-cancer therapeutics. In this study, we determined the anti-angiogenic activity of a single dose of liposomal prednisolone phosphate (PLP-L), by monitoring tumor vascular function and viability over a period of one week. C57BL/6 mice were inoculated subcutaneously with B16F10 melanoma cells. Six animals were PLP-L-treated and six served as control. Tumor tissue and vascular function were probed using MRI before and at three timepoints after treatment. DCE-MRI was used to determine Ktrans, ve, time-to-peak, initial slope and the fraction of non-enhancing pixels, complemented with immunohistochemistry. The apparent diffusion coefficient (ADC), T2 and tumor size were assessed with MRI as well. PLP-L treatment resulted in smaller tumors and caused a significant drop in Ktrans 48 h post-treatment, which was maintained until one week after drug administration. However, this effect was not sufficient to significantly distinguish treated from nontreated animals. The therapy did not affect tumor tissue viability but did prevent the ADC decrease observed in the control group. No evidence for PLP-L-induced tumor vessel normalization was found on histology. Treatment with PLP-L altered tumor vascular function. This effect did not fully explain the tumor growth inhibition, suggesting a broader spectrum of PLP-L activities.",
author = "E. Kluza and M. Heisen and S. Schmid and {Schaft, van der}, D.W.J. and R.M. Schiffelers and G. Storm and {Haar Romeny, ter}, B.M. and G.J. Strijkers and K. Nicolay",
year = "2011",
doi = "10.1007/s10456-010-9198-5",
language = "English",
volume = "14",
pages = "143--153",
journal = "Angiogenesis",
issn = "0969-6970",
publisher = "Springer",
number = "2",

}

Multi-parametric assessment of the anti-angiogenic effects of liposomal glucocorticoids. / Kluza, E.; Heisen, M.; Schmid, S.; Schaft, van der, D.W.J.; Schiffelers, R.M.; Storm, G.; Haar Romeny, ter, B.M.; Strijkers, G.J.; Nicolay, K.

In: Angiogenesis, Vol. 14, No. 2, 2011, p. 143-153.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Multi-parametric assessment of the anti-angiogenic effects of liposomal glucocorticoids

AU - Kluza, E.

AU - Heisen, M.

AU - Schmid, S.

AU - Schaft, van der, D.W.J.

AU - Schiffelers, R.M.

AU - Storm, G.

AU - Haar Romeny, ter, B.M.

AU - Strijkers, G.J.

AU - Nicolay, K.

PY - 2011

Y1 - 2011

N2 - Inflammation plays a prominent role in tumor growth. Anti-inflammatory drugs have therefore been proposed as anti-cancer therapeutics. In this study, we determined the anti-angiogenic activity of a single dose of liposomal prednisolone phosphate (PLP-L), by monitoring tumor vascular function and viability over a period of one week. C57BL/6 mice were inoculated subcutaneously with B16F10 melanoma cells. Six animals were PLP-L-treated and six served as control. Tumor tissue and vascular function were probed using MRI before and at three timepoints after treatment. DCE-MRI was used to determine Ktrans, ve, time-to-peak, initial slope and the fraction of non-enhancing pixels, complemented with immunohistochemistry. The apparent diffusion coefficient (ADC), T2 and tumor size were assessed with MRI as well. PLP-L treatment resulted in smaller tumors and caused a significant drop in Ktrans 48 h post-treatment, which was maintained until one week after drug administration. However, this effect was not sufficient to significantly distinguish treated from nontreated animals. The therapy did not affect tumor tissue viability but did prevent the ADC decrease observed in the control group. No evidence for PLP-L-induced tumor vessel normalization was found on histology. Treatment with PLP-L altered tumor vascular function. This effect did not fully explain the tumor growth inhibition, suggesting a broader spectrum of PLP-L activities.

AB - Inflammation plays a prominent role in tumor growth. Anti-inflammatory drugs have therefore been proposed as anti-cancer therapeutics. In this study, we determined the anti-angiogenic activity of a single dose of liposomal prednisolone phosphate (PLP-L), by monitoring tumor vascular function and viability over a period of one week. C57BL/6 mice were inoculated subcutaneously with B16F10 melanoma cells. Six animals were PLP-L-treated and six served as control. Tumor tissue and vascular function were probed using MRI before and at three timepoints after treatment. DCE-MRI was used to determine Ktrans, ve, time-to-peak, initial slope and the fraction of non-enhancing pixels, complemented with immunohistochemistry. The apparent diffusion coefficient (ADC), T2 and tumor size were assessed with MRI as well. PLP-L treatment resulted in smaller tumors and caused a significant drop in Ktrans 48 h post-treatment, which was maintained until one week after drug administration. However, this effect was not sufficient to significantly distinguish treated from nontreated animals. The therapy did not affect tumor tissue viability but did prevent the ADC decrease observed in the control group. No evidence for PLP-L-induced tumor vessel normalization was found on histology. Treatment with PLP-L altered tumor vascular function. This effect did not fully explain the tumor growth inhibition, suggesting a broader spectrum of PLP-L activities.

U2 - 10.1007/s10456-010-9198-5

DO - 10.1007/s10456-010-9198-5

M3 - Article

C2 - 21225337

VL - 14

SP - 143

EP - 153

JO - Angiogenesis

JF - Angiogenesis

SN - 0969-6970

IS - 2

ER -